This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
What Causes Drawdown In Crypto Portfolios explains the principal triggers of declines in crypto holdings and how to anticipate them with risk-aware planning.
11,735 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
When Micron impresses with double-digit growth, it often sets the mood for the broader memory market. This piece brea...
Nike delivered a quarterly beat that sent its shares higher, but investors kept a close eye on tariffs and future gui...
Investors eye dividend income to replace a $70,000 salary. This piece breaks down three yield-based paths and the cap...
SpaceX stunned markets with a massive IPO haul and a rapid follow-up bond issue. This article breaks down what happen...
Cincinnati Financial boosted its quarterly payout to 94 cents per share, marking an 8% rise and extending a 65-year d...
A fresh analysis shows WisdomTree's WCLD underperforms due to equal-weight rebalancing, turning a $10,000 stake into ...
When a top executive sells shares, investors tune in. This article breaks down what a recent move by Ladder Capital's...
Over the July Fourth weekend, the seventh film animated franchise led the box office, edging out Toy Story 5 as famil...
A 64-year-old with $1.5 million in retirement assets faces a costly year before Medicare, as ACA premiums and uncover...
The S&P 500 trades at 22x forward earnings, but a deeper look at cash flow reveals a 32x multiple, driven by AI-relat...
SpaceX is set to join the Nasdaq-100 on Tuesday, heightening the volatility gap with the S&P 500. The nasdaq-100 been...